Moderna will break ground in mid-2023 on a £150 million complex for the creation of mRNA vaccines and therapeutics in the United Kingdom. Located on the Harwell Campus in Oxfordshire, the Moderna Innovation and Technology Centre (MITC) will comprise two 145,000-sf buildings. The Drug Substance Manufacturing Unit will leverage next-generation automation systems to produce high volumes of vaccine materials, accompanied by an early-stage R&D hub that will support clinical trials. Integrated Project Services is acting as construction manager and engineer for both structures, which are slated for completion in 2025. Additionally, a clinical biomarker lab will be built offsite by Merit for subsequent transport and integration into the state-of-the-art complex. Implementation of a prefabricated modular solution for this specialized environment will significantly accelerate the delivery of the project, enabling operations to commence in just two years.
Questions or Comments? Contact the Editor